
Linde (NasdaqGS:LIN) is back in focus after its recent earnings topped consensus expectations, with management highlighting margin expansion, pricing discipline, and a solid project backlog that supports its projected earnings growth range for 2026.
See our latest analysis for Linde.
Even after the earnings beat and new gas facility plans in North Carolina, the share price has eased slightly in the very short term. However, a 90 day share price return of 13.55% and 1 year total shareholder return of 13.04% point to momentum that has been building rather than fading.
If this kind of steady compounding appeals to you, it could be a good moment to see what else is setting up for potential multi year growth with 18 top founder-led companies
With Linde’s shares delivering strong multi year returns and trading close to analyst targets, the key question now is simple: is there still undervalued upside here, or are markets already pricing in the company’s future growth?
At a last close of $499.65 versus a fair value narrative of $516.41, Linde is framed as slightly undervalued, with that gap tied directly to earnings power and capital allocation.
Linde's ongoing focus on digitalization, operational optimization, and network density, including base volume growth CapEx and bolt-on M&A, should continue to drive self-help margin improvement and support strong operating cash flow and net margin expansion, even through cyclical downturns.
Want to see what is baked into that earnings story? The narrative leans on steady revenue gains, thicker margins, and a richer profit multiple than the wider chemicals group.
Result: Fair Value of $516.41 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, the story can change quickly if prolonged weak industrial demand, especially in Europe and parts of Asia Pacific, or helium oversupply affects pricing and margins.
Find out about the key risks to this Linde narrative.
The fair value narrative suggests Linde is 3.2% undervalued, but its current P/E of 33.6x tells a tougher story. That is higher than the US Chemicals industry at 29.5x and above the fair ratio of 27.6x, so investors are paying a clear premium that adds valuation risk if expectations slip.
On the other hand, Linde trades below the peer average P/E of 38.2x, which hints that some investors might still see relative value against closer comparables. The question is whether you focus on the premium to the wider industry or the discount to peers when judging room for upside.
See what the numbers say about this price — find out in our valuation breakdown.
Given the mix of optimism and caution in this story, it makes sense to move quickly, review the underlying data, and weigh both sides for yourself with 2 key rewards and 2 important warning signs.
If Linde is already on your radar, do not stop there. Expand your watchlist with other focused ideas that could round out your portfolio.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com